Novo Nordisk: Is The GLP-1 Golden Age Already Behind It? [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
NVO's latest GLP-1 drug delivered weaker weight loss than Eli Lilly's, clouding the outlook for the company's next wave of obesity drugs. Competition and drug pricing regulations are driving negative margin surprises. I expect these headwinds to persist. Semaglutide patents are expiring in several large ex-US markets, enabling cheap generics that could cannibalize Ozempic and Wegovy over time and pressure gross margins further. Despite trading at a large discount to its historical and sector PEs, Novo Nordisk's weak technicals and deteriorating fundamentals argue against a near-term rebound. narith_2527/iStock via Getty Images Elevator pitch I see a lot of challenges with Novo Nordisk ( NVO NOVO:CA NONOF Novo Nordisk's share in the obesity and diabetes market is eroding Pricing headwinds are leading to margin deterioration Patent expirations are another Eli Lilly's Zepbound and Mounjaro have overtaken NVO in the U.S. GLP-1 market, with NVO's share declining and cl
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) had its price target raised by Guggenheim from $1,163.00 to $1,183.00. They now have a "buy" rating on the stock.MarketBeat
- Neuroblastoma Treatment Market Analysis Report 2025-2035 - Regional Players and Local Manufacturers are Expected to Play an Important Role in Future Growth [Yahoo! Finance]Yahoo! Finance
- Here is why Eli Lilly (LLY) is Among the 8 Best Beginner Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Samsung Biologics Reports First Quarter 2026 Financial Results [TheStreet.com]TheStreet.com
- Eli Lilly's Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- LLY's page on the SEC website